Pfizer Announces FDA Acceptance for Review of New Drug Application For Tofacitinib

Pfizer announced today that the FDA has accepted for review the NDA for tofacitinib, an investigational, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
MarketWatch